image
Healthcare - Medical - Devices - NASDAQ - US
$ 1.06
-3.64 %
$ 33.8 M
Market Cap
-0.77
P/E
1. INTRINSIC VALUE

Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings.[ Read More ]

The intrinsic value of one CODX stock under the base case scenario is HIDDEN Compared to the current market price of 1.06 USD, Co-Diagnostics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CODX

image
FINANCIALS
6.81 M REVENUE
-80.09%
-42.7 M OPERATING INCOME
-268.43%
-35.3 M NET INCOME
-148.15%
-22.1 M OPERATING CASH FLOW
-336.17%
15.4 M INVESTING CASH FLOW
126.46%
-1.36 M FINANCING CASH FLOW
90.28%
641 K REVENUE
297.97%
-10.2 M OPERATING INCOME
-0.58%
-9.7 M NET INCOME
-27.60%
-7.23 M OPERATING CASH FLOW
-38.92%
4.17 M INVESTING CASH FLOW
203.27%
0 FINANCING CASH FLOW
0.00%
Balance Sheet Decomposition Co-Diagnostics, Inc.
image
Current Assets 62.1 M
Cash & Short-Term Investments 58.5 M
Receivables 331 K
Other Current Assets 3.26 M
Non-Current Assets 33.2 M
Long-Term Investments 773 K
PP&E 6 M
Other Non-Current Assets 26.4 M
Current Liabilities 5.75 M
Accounts Payable 1.48 M
Short-Term Debt 1.68 M
Other Current Liabilities 2.59 M
Non-Current Liabilities 3.56 M
Long-Term Debt 2.15 M
Other Non-Current Liabilities 1.41 M
EFFICIENCY
Earnings Waterfall Co-Diagnostics, Inc.
image
Revenue 6.81 M
Cost Of Revenue 4.18 M
Gross Profit 2.63 M
Operating Expenses 44.1 M
Operating Income -42.7 M
Other Expenses -7.37 M
Net Income -35.3 M
RATIOS
38.57% GROSS MARGIN
38.57%
-626.92% OPERATING MARGIN
-626.92%
-518.68% NET MARGIN
-518.68%
-41.08% ROE
-41.08%
-37.07% ROA
-37.07%
-45.59% ROIC
-45.59%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Co-Diagnostics, Inc.
image
Net Income -35.3 M
Depreciation & Amortization 1.23 M
Capital Expenditures -1.37 M
Stock-Based Compensation 8.34 M
Change in Working Capital 5.64 M
Others 1.38 M
Free Cash Flow -23.4 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Co-Diagnostics, Inc.
image
Wall Street analysts predict an average 1-year price target for CODX of $9 , with forecasts ranging from a low of $6 to a high of $12 .
CODX Lowest Price Target Wall Street Target
6 USD 466.04%
CODX Average Price Target Wall Street Target
9 USD 749.06%
CODX Highest Price Target Wall Street Target
12 USD 1032.08%
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION
6. Ownership
Insider Ownership Co-Diagnostics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Mar 20, 2023
Bought 5.7 K USD
Brown Brian Lee
Chief Financial Officer
+ 3000
1.899 USD
3 years ago
Sep 08, 2021
Sell 20.9 K USD
Durenard Eugene
Director
- 2000
10.455 USD
3 years ago
May 19, 2021
Sell 93.2 K USD
BENSON REED L
General Counsel
- 10920
8.5377 USD
3 years ago
May 19, 2021
Sell 830 K USD
BENSON REED L
General Counsel
- 97413
8.5244 USD
3 years ago
May 19, 2021
Sell 8.53 USD
BENSON REED L
General Counsel
- 1
8.53 USD
3 years ago
Jan 15, 2021
Sell 419 K USD
Egan Dwight H
Chief Executive Officer
- 38046
11 USD
3 years ago
Jan 14, 2021
Sell 103 K USD
SERBIN RICHARD S
Director
- 10000
10.29 USD
3 years ago
Jan 13, 2021
Sell 106 K USD
Durenard Eugene
Director
- 10500
10.09 USD
3 years ago
Jan 13, 2021
Sell 121 K USD
NELSON JAMES B
Director
- 11900
10.13 USD
3 years ago
Jan 13, 2021
Sell 6.08 K USD
NELSON JAMES B
Director
- 600
10.14 USD
3 years ago
Dec 14, 2020
Sell 172 K USD
SERBIN RICHARD S
Director
- 17000
10.1 USD
3 years ago
Dec 10, 2020
Sell 102 K USD
Durenard Eugene
Director
- 10000
10.15 USD
3 years ago
Nov 25, 2020
Sell 940 K USD
BENSON REED L
CFO and Secretary
- 89524
10.5 USD
3 years ago
Nov 24, 2020
Sell 470 K USD
Egan Dwight H
Chief Executive Officer
- 44764
10.51 USD
3 years ago
Nov 23, 2020
Sell 747 K USD
Egan Dwight H
Chief Executive Officer
- 71569
10.44 USD
3 years ago
Nov 20, 2020
Sell 200 K USD
Egan Dwight H
Chief Executive Officer
- 18017
11.09 USD
4 years ago
May 20, 2020
Sell 451 K USD
Durenard Eugene
Director
- 25000
18.03 USD
4 years ago
May 26, 2020
Sell 456 K USD
Durenard Eugene
Director
- 25000
18.24 USD
4 years ago
May 20, 2020
Sell 460 K USD
Durenard Eugene
Director
- 25000
18.4 USD
4 years ago
May 26, 2020
Sell 457 K USD
Durenard Eugene
Director
- 25000
18.26 USD
4 years ago
May 19, 2020
Sell 462 K USD
SERBIN RICHARD S
Director
- 25000
18.5 USD
4 years ago
May 28, 2020
Sell 316 K USD
SERBIN RICHARD S
Director
- 17500
18.03 USD
4 years ago
May 28, 2020
Sell 135 K USD
SERBIN RICHARD S
Director
- 7500
18 USD
6 years ago
May 11, 2018
Bought 2.38 K USD
Satterfield Brent
Chief Science Officer
+ 1305
1.82 USD
6 years ago
May 03, 2018
Bought 955 USD
Satterfield Brent
Chief Science Officer
+ 500
1.91 USD
6 years ago
Apr 23, 2018
Bought 1.01 K USD
Satterfield Brent
Chief Science Officer
+ 500
2.02 USD
6 years ago
Apr 16, 2018
Bought 970 USD
Satterfield Brent
Chief Science Officer
+ 500
1.94 USD
6 years ago
Apr 09, 2018
Bought 4.92 K USD
Satterfield Brent
Chief Science Officer
+ 2400
2.05 USD
6 years ago
Apr 09, 2018
Bought 11.8 M USD
Satterfield Brent
Chief Science Officer
+ 2400
4920 USD
7. News
Co-Diagnostics, Inc. (CODX) Q3 2024 Earnings Call Transcript Co-Diagnostics, Inc. (NASDAQ:CODX ) Q3 2024 Results Conference Call November 7, 2024 4:30 PM ET Company Participants Andrew Benson - Head of Investor Relations. Dwight Egan - CEO Brian Brown - CFO Conference Call Participants Jade Montgomery - H.C. seekingalpha.com - 1 week ago
Co-Diagnostics, Inc. (CODX) Reports Q3 Loss, Tops Revenue Estimates Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.32 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.20 per share a year ago. zacks.com - 1 week ago
Co-Diagnostics, Inc. Reports Third Quarter 2024 Financial Results SALT LAKE CITY , Nov. 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced financial results for the quarter ended September 30, 2024. Third Quarter 2024 Financial Results: Revenue of $0.6 million, which declined from $2.5 million during the prior year primarily due to timing of grant revenue recognition. prnewswire.com - 1 week ago
Co-Diagnostics, Inc. to Host Booth at MEDICA Trade Fair in Düsseldorf, Germany on Nov 11-14, 2024 SALT LAKE CITY , Nov. 5, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be hosting a booth and delivering a presentation at the MEDICA 2024 trade fair in Düsseldorf, Germany on November 11-14. MEDICA has become the largest medical B2B trade fair in the world, attracting 83,000 visitors and over 5,300 exhibitors from almost 70 countries. prnewswire.com - 1 week ago
Co-Diagnostics, Inc. Announces Third Quarter 2024 Earnings Release Date and Webcast SALT LAKE CITY , Oct. 25, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today it will release its third quarter 2024 results on Thursday, November 7, 2024, after the market close. The Company will also host a conference call and webcast on the same day at 4:30 p.m. prnewswire.com - 3 weeks ago
Co-Diagnostics, Inc. to Host Booth at Medlab Africa in Cape Town on Oct 22-24, 2024 SALT LAKE CITY , Oct. 21, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be hosting a booth at Africa Health/Medlab Africa in Cape Town, South Africa on October 22-24, 2024. The conference website describes it as the largest gathering of healthcare companies, technology, products and services in the sub-Saharan region, catering to an audience of distributors, government representatives, laboratory executives, and purchasing/procurement managers from the South African Development Community region and around the world, who attend to meet with world-class suppliers and manufacturers. prnewswire.com - 3 weeks ago
Co-Diagnostics, Inc. to Host Booth at the 2024 UHCA/UCAL Fall Convention & Expo on Oct 2-3 SALT LAKE CITY , Oct. 2, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that Co-Diagnostics will be hosting a booth at the Utah Health Care Association/Utah Center for Assisted Living (UHCA/UCAL) Convention & Expo at the Mountain America Expo Center in Sandy, Utah on October 2-3, 2024. The UHCA/UCAL Convention includes sessions and events for executive leadership, administrators, corporate personnel, owners, and Directors of Nursing for skilled nursing, assisted living and intermediate care facilities, and will include an expo for companies to exhibit their products and services relevant to these industries. prnewswire.com - 1 month ago
Co-Diagnostics, Inc. to Accompany Utah Governor and WTC Utah on Trade Mission to South Korea and Japan SALT LAKE CITY , Sept. 24, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced Company representatives will be accompanying Utah Governor Cox and the Governor's Office of Economic Opportunity, as part of the latest World Trade Center (WTC) Utah trade mission to South Korea and Japan from September 24-October 5. prnewswire.com - 1 month ago
Co-Diagnostics, Inc. Completes Updated Clade Ib Analysis of 2-Gene Mpox RUO Test SALT LAKE CITY , Sept. 5, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that the Company has performed an in silico analysis of the Co-Dx™ Logix Smart® Mpox (2-Gene) RUO test to evaluate the possible impact of clade Ib mpox on the test. prnewswire.com - 2 months ago
Co-Diagnostics, Inc. to Present at 16th Next Generation Dx Summit in Washington, D.C. SALT LAKE CITY , Aug. 15, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq-CM: CODX) (the "Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that it will be sponsoring, presenting and hosting a booth at the 16th Annual Next Generation Dx Summit, held virtually and in-person in Washington, D.C. on August 19-21, 2024. prnewswire.com - 3 months ago
Co-Diagnostics, Inc. (CODX) Q2 2024 Earnings Call Transcript Co-Diagnostics, Inc. (NASDAQ:CODX ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Andrew Benson - Head, Investor Relations Dwight Egan - Chief Executive Officer Brian Brown - Chief Financial Officer Conference Call Participants Jade Montgomery - H.C. Wainwright Operator Good day, and welcome to the Co-Diagnostics Second Quarter 2024 Earnings Conference Call. seekingalpha.com - 3 months ago
Co-Diagnostics, Inc. (CODX) Reports Q2 Loss, Tops Revenue Estimates Co-Diagnostics, Inc. (CODX) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.31 per share a year ago. zacks.com - 3 months ago
8. Profile Summary

Co-Diagnostics, Inc. CODX

image
COUNTRY US
INDUSTRY Medical - Devices
MARKET CAP $ 33.8 M
Dividend Yield 0.00%
Description Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers polymerase chain reaction (PCR) diagnostic tests for COVID-19, tuberculosis, hepatitis B and C, human papilloma virus, malaria, chikungunya, dengue, and the zika virus; three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; and molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. The company also provides tests that identify genetic traits in plant and animal genomes; and portable PCR device designed to bring PCR to patients in point-of-care and at-home settings. In addition, it intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Contact 2401 South Foothill Drive, Salt Lake City, UT, 84109 https://www.codiagnostics.com
IPO Date July 12, 2017
Employees 155
Officers Mr. Brian L. Brown CPA Chief Financial Officer & Company Secretary Mr. Andrew Benson Head of Investor Relations Dr. Mayuranki Almaula Senior Vice President of Overseas Operations & Strategic Alliances Mr. Richard David Abbott President Mr. Christopher Thurston Chief Technology Officer Mr. Cameron Gundry Head of Commercialization LATAM/EUR Mr. Dwight H. Egan Chairman & Chief Executive Officer Dr. Brent C. Satterfield Ph.D. Co-Founder & Member of Scientific Advisory Board Mr. David Nielsen Chief Operating Officer Mr. Dan Bohrer CPA Vice President of Finance & Accounting